LAVAL, QC, May 31, 2012 /CNW/ - Gamma-Dynacare Medical Laboratories today announced the introduction of a second advanced screening test for colorectal cancer, the fecal immunochemical test (FIT).

The U.S. Preventive Services Task Force recommends colorectal cancer screening for all adults starting at age 45. After age 75, the task force recommends talking with your health care team to decide ...

Noninvasive surveillance with multitarget stool DNA testing or fecal immunochemical testing (FIT) could potentially match colonoscopy for reducing long-term colorectal cancer (CRC) incidence and ...

Marie looked down at her toilet, a paper plate in one hand and a stool testing kit in the other, and wondered, “Do I really have to do this?” When she turned 50, her doctor had recommended checking ...

Multitarget stool-based tests are showing promise for colorectal cancer (CRC) screening in average-risk individuals and could edge out the current standard fecal immunochemical test (FIT). These new ...

More than 10% of fecal immunochemical test (FIT)–based colorectal cancer screening could not be processed due to unsatisfactory samples. Colorectal cancer (CRC) screening using the fecal ...

Colorectal cancer continues to be one of the leading causes of cancer-related deaths worldwide. However, recent advancements in medical screening have brought new hope in the fight against this deadly ...

This indicates that the test is as effective as colonoscopy in reducing colorectal cancer mortality in screening [programs],” ...

Commercial FITs can match NG-MSDT diagnostic results for CRC by lowering the positivity threshold, enhancing sensitivity while maintaining specificity. FITs are accessible, noninvasive CRC screening ...

I read with interest the CMAJ article “The appropriate use of fecal immunochemical testing”1 (FIT). However, I would argue strongly that the newer FIT (but not the traditional FOBT) are very useful in ...

Annual FIT-based screening produced fewer CRC cases, fewer CRC deaths and more life years gained versus all other strategies, even at real-world adherence rates. Every screening strategy that was ...